Shire Continues to Deliver Excellent Growth From Cor...(to to to to ...),Health

Date:10/30/2009

to to to to September September September September 30, 30, 30, 30, 2009 2008 2009 2008 $M $M $M $M Income/(loss) from continuing operations 59.6 (35.3) 329.5 14.3 Loss from discontinued operations - (0.9) (12.4) (0.9) Noncontrolling interest in subsidiaries - 1.3 0.2 1.3 Numerator for basic and diluted EPS(1) 59.6 (34.9) 317.3 14.7 Weighted average number of shares: Millions Millions Millions Millions Basic(2) 540.6 540.3 540.0 542.6 Effect of dilutive shares: Stock options(3) 7.7 - 7.1 2.7 Diluted 548.3 540.3 547.1 545.3 (1) For the three and nine month periods ended September 30, 2009 and 2008 interest on the convertible bonds has not been added back as the effect would be anti-dilutive for all periods presented. (2) Excludes shares purchased by the ESOT and presented by the Company as treasury stock. (3) Calculated using the treasury stock method.

The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:

                          3 months to  3 months to  9 months to  9 months to
                            September    September    September    September
                                   30,          30,          30,          30,
                                 2009         2008         2009       
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease